• Strengthened balance sheet through $600m capital raise
• Progressed clinical trials for PKD, ADOA, RP11, and PMS programs
• Received FDA alignment on RP11 registrational study design

PYC Therapeutics, a precision medicine company, provided an update on its progress in the first quarter of 2026. The key highlights include: strengthening of the company's balance sheet through a $600 million capital raise, progression of clinical trials for its polycystic kidney disease (PKD), autosomal dominant optic atrophy (ADOA), retinitis pigmentosa type 11 (RP11), and Phelan-McDermid Syndrome (PMS) programs. In the PKD program, PYC initiated dosing of the highest dose cohort in the Single Ascending Dose (SAD) study and is preparing for the commencement of the Multiple Ascending Dose (MAD) study in Q2 2026. In the ADOA program, PYC progressed enrolment in the 10 and 30-microgram repeat dose cohorts and completed enrolment of the 60-microgram single dose cohort. In the RP11 program, PYC held a Type D meeting with the FDA, which confirmed key elements of the registrational study design required to support a New Drug Application. In the PMS program, PYC advanced its Dose-Range Finding (DRF) studies in both rodents and Non-Human Primates ahead of the proposed Good Laboratory Practice (GLP) toxicology studies scheduled to commence in Q2 2026.